Suppression of cytokine release syndrome by conjugating TCR-signaling-responsive siltuximab nanogels with CAR-T cells

Chimeric antigen receptor T-cells (CAR-T) therapy has demonstrated significant anti-tumor responses in hematological malignancies and even solid tumors. However, the overactivation of CAR-T cells in vivo can lead to cytokine release syndrome (CRS), with the unpredictable timing and severity of its o...

Descrición completa

Detalles Bibliográficos

Principais autores:	Haimei Li, Zichen Wang, Liang Huang, Yi Liu, Peng Jiang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Tsinghua University Press 2025-11-01
Series:	Nano Research
Assuntos:	chimeric antigen receptor t-cells (car-t) cytokine release syndrome siltuximab nanogels reductive environment tumor therapy
Acceso en liña:	https://www.sciopen.com/article/10.26599/NR.2025.94908075
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!